| Literature DB >> 25366070 |
Suk Jin Choi1, Yeon Il Choi1, Lucia Kim1, In Suh Park1, Jee Young Han1, Joon Mee Kim1, Young Chae Chu1.
Abstract
BACKGROUND: Inevitable loss of diagnostic material should be minimized during cell block preparation. We introduce a modified agarose cell block technique that enables the synthesis of compact cell blocks by using the entirety of a cell pellet without the loss of diagnostic material during cell block preparations. The feasibility of this technique is illustrated by high-throughput immunocytochemistry using high-density cell block microarray (CMA).Entities:
Keywords: Biopsy, fine-needle; Cell block microarray; Immunocytochemistry; Paraffin embedding; Sepharose
Year: 2014 PMID: 25366070 PMCID: PMC4215960 DOI: 10.4132/KoreanJPathol.2014.48.5.351
Source DB: PubMed Journal: Korean J Pathol ISSN: 1738-1843
Fig. 1.Schematic flow chart of the protocol for preparation of compact agarose cell blocks from the residues of liquid-based cytology samples.
Fig. 2.Agarose cell block preparation. The residue of a SurePath sample is placed in Eppendorf reaction tubes and fixed in formalin (A). Then, the material is pelleted and resuspended with a minimal volume of 3% (w/v) ultra-low gelling temperature agarose solution at room temperature and the resulting agarose cell suspension is allowed to gelate in the refrigerator at 4°C (B). Each of the solidified agarose cell buttons is transferred into the cap of the tube (C). Then, the cap with an agarose cell button at the bottom is filled with 3% standard agarose solution (D). The resulting agarose gel disk is removed from the cap with the aid of a 23-gauge needle (E) and then subjected to tissue processing for paraffin embedding. When the agarose gel disk is fractured during this step, it is carefully reconstructed and put in a tissue embedding mold and re-embedded in additional 3% standard agarose solution (F). The agarose cell block is trimmed to expose the agarose cell button (G). If a small piece of redundant formalin-fixed tissue (arrows) is embedded in advance in parallel with the cell button, it can be effectively used as a visible marker indicating the optimal cutting level of the cell block (H). Reconstructed gel disks are processed in the same way and embedded in paraffin blocks (I).
Fig. 3.Construction of a cell block microarray (CMA) for high-throughput immunocytochemistry of cell blocks. A 3-mm tissue punch is used to extract cores of agarose cell buttons from the agarose cell blocks and implant them in a ready-to-use homemade recipient agarose paraffin block (A, B). The CMA is completely melted on a heat plate to facilitate complete integration of cell block cores into the recipient agarose paraffin block (C, D). Finally, the CMA is re-embedded in paraffin and trimmed to expose the cell block cores (E, F).
Sources and dilutions of antibodies used for immunocytochemistry of the cell block microarray
| Target | Source | Dilution |
|---|---|---|
| Cytokeratin 19 | Dako | 1:200 |
| Galectin-3 | Novocastra | 1:500 |
| Thyroid transcription factor-1 | NeoMarkers | 1:1,500 |
| Thyroglobulin | NeoMarkers | 1:1,500 |
| Parathyroid hormone | NeoMarkers | 1:400 |
| CD56 | Novocastra | 1:400 |
| HBME1 | Cell Marque | 1:400 |
| D2-40 | Dako | 1:300 |
| Wilms’ tumor-1 | Cell Marque | 1:500 |
| Calretinin | Chemicon | 1:1,800 |
| Leukocyte common antigen (CD45) | Dako | 1:2,000 |
| CD20 | Pharmingen | 1:100 |
| CD3 | Dako | 1:100 |
| Terminal deoxynucleotidyl transferase | Cell Marque | 1:400 |
| PAX5 | Cell Marque | 1:400 |
Fig. 4.Representative SurePath smears and corresponding agarose cell blocks of thyroid fine needle aspirations. High cellularity in a SurePath smear of papillary thyroid carcinoma (A) correlates well with that of the agarose cell block section (B). Low cellularity in a SurePath smear of subacute granulomatous thyroiditis (C) correlates well with that of the agarose cell block section (D). Insets depict high power views.
Fig. 5.SurePath smears and corresponding agarose cell blocks of serous effusions. The cellularities in SurePath smears of serous effusions with reactive mesothelial proliferation (A), malignant mesothelioma (B), and metastatic adenocarcinoma (C) correlate well with those of corresponding agarose cell block sections (D-F), respectively.
Fig. 6.Representative cytology spots on a section of cell block microarray. Depending on the cellularities of corresponding SurePath smears, the cytology spots on the cell block microarray showed various cellularities (A, H&E). The cytoarchitectural and immunocytochemical features of malignant serous effusion (B, H&E [left] and D2-40 [right]) and atypical thyroid fine needle aspirate (C, H&E [left] and cytokeratin 19 [right]) are supportive for more specific and more confidential diagnosis, respectively.
Cytologic samples incorporated into cell block microarray and result of immunocytochemistry
| Samples | Site | Diagnosis of smears | Supportive immunocytochemistry of cell block* | Diagnosis based on ICC |
|---|---|---|---|---|
| LBC_FNAs (SurePath) | Thyroid | Papillary carcinoma (n=8) | TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– | Papillary thyroid carcinoma |
| Suspicious for papillary carcinoma (n=2) | TG+, TTF1+, CK19+, galectin 3+, CD56–, HBME1+, PTH– | Papillary thyroid carcinoma | ||
| Nodular hyperplasia (n=12) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Nodular hyperplasia | ||
| Atypia (n=4) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Nodular hyperplasia | ||
| Atypia (n=1) | TG–, TTF1–, CK19+, galectin 3–, CD56–, HBME1–, PTH+ | Parathyroid lesion | ||
| Benign Hurthle cell proliferation (n=2) | TG+, TTF1+, CK19–, galectin 3–, CD56+, HBME1–, PTH– | Benign Hurthle cell lesion | ||
| Chronic lymphocytic thyroiditis (n=2) | N/A due to scanty cellularity | N/A | ||
| Lymph node | Lymphoid malignancy (n=2) | CD45–, CD20–, CD3–, TdT+, PAX5+, CD56– | B-lymphoblastic lymphoma | |
| CD45+, CD20+, CD3–, TdT–, PAX5+, CD56– | Large B-cell lymphoma | |||
| LBC_serous effusions (SurePath) | Ascitic fluid | Lymphoid malignancy (n=1) | CD45+, CD20–, CD3–, TdT+, PAX5+, CD56– | B-lymphoblastic lymphoma |
| Adenocarcinoma (n=1) | CK7+, CK19+, calretinin–, D2-40, WT1+, CD56–, TTF1– | Ovarian serous carcinoma | ||
| Pleural effusion | Adenocarcinoma (n=1) | CK7+, CK19+, calretinin–, D2-40–, HBME1–, WT1–, TTF1+ | Adenocarcinoma of lung primary | |
| Favor malignant mesothelioma (n=1) | CK7+, CK19+, calretinin+, D2-40+, HBME1+, WT1+, TTF1– | Malignant mesothelioma | ||
| Negative for malignancy (n=1) | N/A | N/A |
ICC, immunocytochemistry; LBC, liquid-based cytology; FNA, fine needle aspiration; cytokeratin; TG, thyroglobulin; TTF1, thyroid transcription factor-1; CK, cytokeratin; PTH, parathyroid hormone; N/A, not applicable; TdT, terminal deoxynucleotidyl transferase; WT1, Wilms’ tumor-1.
Fig. 7.SurePath smear and agarose cell block from parathyroid lesion. The SurePath sample is allegedly from an intrathyroidal nodule. The smear (A–C) with cohesive clusters and solid sheets of relatively monomorphic epithelial cells was interpreted as “atypia of undetermined significance.” The diagnosis is confirmed by cytoarchitectural examination (D–F) and immunocytochemical analysis (G, thyroglobulin; H, thyroid transcription factor-1; I, parathyroid hormone; arrows indicating positive and negative controls) of cell block sections.